Brooklyn ImmunoTherapeutics Common Stock

As of the most recent data (December 2025), BTX shows a common stock of $2.8B. That compares with $3.7B in the prior-year period — down 23.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BTX's common stock is now $2.8B (was $3.7B) — a 23.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Brooklyn ImmunoTherapeutics is outperforming or lagging.

Tracking BTX's common stock over time shows whether Brooklyn ImmunoTherapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $2.8B That compares with $3.7B in the prior-year period — down 23.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this common stock page, Stockcircle has Brooklyn ImmunoTherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect common stock (currently $2.8B) with ownership activity and broader fundamentals.

Brooklyn ImmunoTherapeutics's common stock is $2.8B; compare it with other Telecommunications names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.